Kelsey R. Sewell, Lauren E. Oberlin, Thomas K. Karikari, Marcos Olvera-Rojas, Lu Wan, Jill K. Morris, Paul J. Kueck, Xuemei Zeng, Haiqing Huang, George Grove, Yijun Chen, Tara K. Lafferty, Anuradha Sehrawat, M. Ilyas Kamboh, Anna L. Marsland, Arthur F. Kramer, Edward McAuley, Jeffrey M. Burns, Charles H. Hillman, Eric D. Vidoni, Chaeryon Kang, Kirk I. Erickson
{"title":"Blood biomarkers differentiate AD-related versus non-AD-related cognitive deficits","authors":"Kelsey R. Sewell, Lauren E. Oberlin, Thomas K. Karikari, Marcos Olvera-Rojas, Lu Wan, Jill K. Morris, Paul J. Kueck, Xuemei Zeng, Haiqing Huang, George Grove, Yijun Chen, Tara K. Lafferty, Anuradha Sehrawat, M. Ilyas Kamboh, Anna L. Marsland, Arthur F. Kramer, Edward McAuley, Jeffrey M. Burns, Charles H. Hillman, Eric D. Vidoni, Chaeryon Kang, Kirk I. Erickson","doi":"10.1002/alz.14619","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>The utility of blood-based biomarkers for discriminating Alzheimer's disease (AD)-related versus non-AD-related cognitive deficits in preclinical populations remains poorly understood. Here, we tested the capability of blood markers to detect and discriminate variation in performance across multiple cognitive domains in a cognitively unimpaired sample.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Participants (<i>n </i>= 648, aged 69.9 ± 3.8, 71% female) underwent a comprehensive cognitive assessment and assays for plasma-based biomarkers amyloid beta (Aβ)1-42/1-40 by mass spectrometry, phosphorylated tau (p-tau) 181 and 217, p-tau217/Aβ1-42, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Greater p-tau217 was exclusively associated with poorer episodic memory performance (β = −0.11, SE = 0.04, <i>p </i>= .003), and remained so after covarying for NfL. Higher NfL was non-specifically associated with poorer performance across a range of cognitive domains and remained so after covarying for p-tau217.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Blood-based biomarkers may differentiate non-AD-related versus AD-related cognitive deficits. This characterization will be important for early intervention and disease monitoring for AD.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>There is heterogeneity in the causes of cognitive decline in aging.</li>\n \n <li>AD-related blood biomarkers may help characterize these causes.</li>\n \n <li>Elevated p-tau217 was exclusively associated with poorer episodic memory.</li>\n \n <li>Elevated NfL was associated with poorer cognition in a broad range of domains.</li>\n \n <li>Blood biomarkers may help differentiate AD- and non-AD-related cognitive deficits.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 3","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14619","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14619","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
The utility of blood-based biomarkers for discriminating Alzheimer's disease (AD)-related versus non-AD-related cognitive deficits in preclinical populations remains poorly understood. Here, we tested the capability of blood markers to detect and discriminate variation in performance across multiple cognitive domains in a cognitively unimpaired sample.
METHODS
Participants (n = 648, aged 69.9 ± 3.8, 71% female) underwent a comprehensive cognitive assessment and assays for plasma-based biomarkers amyloid beta (Aβ)1-42/1-40 by mass spectrometry, phosphorylated tau (p-tau) 181 and 217, p-tau217/Aβ1-42, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL).
RESULTS
Greater p-tau217 was exclusively associated with poorer episodic memory performance (β = −0.11, SE = 0.04, p = .003), and remained so after covarying for NfL. Higher NfL was non-specifically associated with poorer performance across a range of cognitive domains and remained so after covarying for p-tau217.
DISCUSSION
Blood-based biomarkers may differentiate non-AD-related versus AD-related cognitive deficits. This characterization will be important for early intervention and disease monitoring for AD.
Highlights
There is heterogeneity in the causes of cognitive decline in aging.
AD-related blood biomarkers may help characterize these causes.
Elevated p-tau217 was exclusively associated with poorer episodic memory.
Elevated NfL was associated with poorer cognition in a broad range of domains.
Blood biomarkers may help differentiate AD- and non-AD-related cognitive deficits.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
